MX2020003004A - Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos. - Google Patents
Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos.Info
- Publication number
- MX2020003004A MX2020003004A MX2020003004A MX2020003004A MX2020003004A MX 2020003004 A MX2020003004 A MX 2020003004A MX 2020003004 A MX2020003004 A MX 2020003004A MX 2020003004 A MX2020003004 A MX 2020003004A MX 2020003004 A MX2020003004 A MX 2020003004A
- Authority
- MX
- Mexico
- Prior art keywords
- adults
- synthetic
- treatment
- cannabidiol
- focal epilepsy
- Prior art date
Links
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 title abstract 3
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 title abstract 3
- 229950011318 cannabidiol Drugs 0.000 title abstract 3
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 title abstract 3
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 title abstract 3
- 206010061334 Partial seizures Diseases 0.000 title 1
- 201000007186 focal epilepsy Diseases 0.000 title 1
- 206010010904 Convulsion Diseases 0.000 abstract 2
- 206010015037 epilepsy Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762560446P | 2017-09-19 | 2017-09-19 | |
| US201762593575P | 2017-12-01 | 2017-12-01 | |
| US201862613160P | 2018-01-03 | 2018-01-03 | |
| US201862652995P | 2018-04-05 | 2018-04-05 | |
| US201862660198P | 2018-04-19 | 2018-04-19 | |
| PCT/IB2018/057189 WO2019058261A1 (en) | 2017-09-19 | 2018-09-18 | TRANSDERMAL SYNTHETIC CANNABIDIOL FOR THE TREATMENT OF FOCAL EPILEPSY IN ADULTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020003004A true MX2020003004A (es) | 2020-11-06 |
Family
ID=63762572
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020003004A MX2020003004A (es) | 2017-09-19 | 2018-09-18 | Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos. |
| MX2024002904A MX2024002904A (es) | 2017-09-19 | 2020-03-18 | Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024002904A MX2024002904A (es) | 2017-09-19 | 2020-03-18 | Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos. |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20190083388A1 (https=) |
| EP (1) | EP3684411A1 (https=) |
| JP (2) | JP2020534362A (https=) |
| KR (1) | KR20200055067A (https=) |
| AU (1) | AU2018337933A1 (https=) |
| BR (1) | BR112020004947A2 (https=) |
| CA (1) | CA3075719A1 (https=) |
| IL (2) | IL301910A (https=) |
| JO (1) | JOP20200045A1 (https=) |
| MX (2) | MX2020003004A (https=) |
| WO (1) | WO2019058261A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3733156A1 (de) * | 2019-05-02 | 2020-11-04 | Gábor Fóti | C.b.d.m therapie |
| BR112022004175A2 (pt) * | 2019-09-17 | 2022-05-31 | Zynerba Pharmaceuticals Inc | Tratamento de encefalopatia de syngap1 |
| AU2020358869A1 (en) | 2019-10-03 | 2022-04-14 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| US12409131B2 (en) | 2019-10-03 | 2025-09-09 | Pike Therapeutics Usa, Inc. | Transdermal delivery of dronabinol |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| EP4041209A4 (en) * | 2019-10-11 | 2024-01-24 | Pike Therapeutics, Inc. | TRANSDERMAL COMPOSITIONS COMPRISING CANNABIDIOL (CBD) FOR USE IN THE TREATMENT OF EPILEPTIC DISORDERS |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| CA3155181A1 (en) | 2019-10-14 | 2021-04-22 | Pike Therapeutics, Inc., 1219014 B.C. Ltd. | Transdermal delivery of cannabidiol |
| US12268699B2 (en) | 2019-10-14 | 2025-04-08 | Pike Therapeutics Inc. | Transdermal delivery of tetrahydrocannabinol |
| GB2597287A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to structural abnormalities of the brain |
| US20220047525A1 (en) * | 2020-08-17 | 2022-02-17 | Pike Therapeutics, Inc. | Transdermal pharmaceutical formulations of nabilone alone and in combination with cannabinoids |
| KR20230113622A (ko) * | 2020-12-03 | 2023-07-31 | 지네르바 파마슈티컬스, 인코포레이티드 | 난치성 발작의 치료를 위한 칸나비디올 |
| AU2022255944A1 (en) * | 2021-04-08 | 2023-10-12 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2760460C (en) | 2009-04-28 | 2019-04-02 | Alltranz Inc. | Transdermal formulations of cannabidiol comprising a penetration enhancer and methods of using the same |
| PT2473475T (pt) * | 2009-08-31 | 2017-08-02 | Zynerba Pharmaceuticals Inc | Utilização de profármacos de canabidiol na administração tópica e transdérmica com microagulhas |
| GB2530001B (en) * | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2539472A (en) * | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2541191A (en) * | 2015-08-10 | 2017-02-15 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
-
2018
- 2018-09-18 US US16/133,930 patent/US20190083388A1/en not_active Abandoned
- 2018-09-18 AU AU2018337933A patent/AU2018337933A1/en not_active Abandoned
- 2018-09-18 JP JP2020537297A patent/JP2020534362A/ja active Pending
- 2018-09-18 IL IL301910A patent/IL301910A/en unknown
- 2018-09-18 KR KR1020207011219A patent/KR20200055067A/ko not_active Ceased
- 2018-09-18 JO JOP/2020/0045A patent/JOP20200045A1/ar unknown
- 2018-09-18 WO PCT/IB2018/057189 patent/WO2019058261A1/en not_active Ceased
- 2018-09-18 EP EP18782520.3A patent/EP3684411A1/en not_active Ceased
- 2018-09-18 MX MX2020003004A patent/MX2020003004A/es unknown
- 2018-09-18 BR BR112020004947-6A patent/BR112020004947A2/pt unknown
- 2018-09-18 CA CA3075719A patent/CA3075719A1/en active Pending
-
2020
- 2020-02-20 IL IL272818A patent/IL272818A/en unknown
- 2020-03-18 MX MX2024002904A patent/MX2024002904A/es unknown
- 2020-08-18 US US16/996,082 patent/US20210030665A1/en not_active Abandoned
-
2023
- 2023-09-08 JP JP2023145851A patent/JP7650929B2/ja active Active
-
2024
- 2024-07-05 US US18/765,056 patent/US20250213465A1/en active Pending
-
2025
- 2025-01-28 US US19/039,288 patent/US20250302734A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2020534362A (ja) | 2020-11-26 |
| AU2018337933A1 (en) | 2020-03-12 |
| WO2019058261A1 (en) | 2019-03-28 |
| US20250302734A1 (en) | 2025-10-02 |
| CA3075719A1 (en) | 2019-03-28 |
| US20210030665A1 (en) | 2021-02-04 |
| JOP20200045A1 (ar) | 2020-02-27 |
| US20190083388A1 (en) | 2019-03-21 |
| MX2024002904A (es) | 2024-04-04 |
| WO2019058261A9 (en) | 2019-07-04 |
| IL301910A (en) | 2023-06-01 |
| IL272818A (en) | 2020-04-30 |
| EP3684411A1 (en) | 2020-07-29 |
| JP2023171776A (ja) | 2023-12-05 |
| JP7650929B2 (ja) | 2025-03-25 |
| BR112020004947A2 (pt) | 2020-09-15 |
| US20250213465A1 (en) | 2025-07-03 |
| KR20200055067A (ko) | 2020-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020003004A (es) | Cannabidiol transdermico sintetico para el tratamiento de epilepsia focal en adultos. | |
| EP4414030A3 (en) | Treatment of fragile x syndrome with cannabidiol | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| JOP20220061A1 (ar) | علاج الضعف السلوكي في الاعتلال الدماغي النموي والصرعي | |
| PH12017500933A1 (en) | Sublingual administration of riluzole | |
| PH12015502075B1 (en) | Treatment of cataplexy | |
| CL2017002242A1 (es) | Método para tratar un tumor cerebral | |
| AU2016255707A8 (en) | Uses of cannabidiol for treatment of infantile spasms | |
| EP4039247A3 (en) | Sublingual formulation of riluzole | |
| MX2015009209A (es) | Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos. | |
| TN2019000019A1 (en) | Treatment and prevention of sleep disorders | |
| MX394355B (es) | Método de tratamiento de meduloblastoma con un inhibidor de ezh2. | |
| EP4681708A3 (en) | Methods of treating pah with combinations of ralinepag and other agents | |
| NZ722600A (en) | Methods of treating mild brain injury | |
| MX357763B (es) | Tratamiento para cancer pancreatico. | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. | |
| IN2014DN09990A (https=) | ||
| BR112018069174A2 (pt) | tratamento de prurido urêmico | |
| MX2013011694A (es) | Analogos de taxano y abeo-taxanos. | |
| WO2014153505A3 (en) | Treatment of chemotherapy-induced peripheral neuropathy | |
| EA201790220A1 (ru) | Лечение симптомов, связанных с андроген-депривационной терапией | |
| MX2023003924A (es) | Metodos de administracion de tratamiento antifibrotico. | |
| NZ703905A (en) | Method of treating multiple sclerosis by using narrow band uvb | |
| UA108484U (uk) | Спосіб лікування хворих на неходжкінську первинну медіастинальну в-великоклітинну лімфому | |
| UA127603U (uk) | Спосіб симптоматичного лікування свербежу |